Previous Close | 43.56 |
Open | 43.70 |
Bid | 40.35 x 1800 |
Ask | 43.12 x 800 |
Day's Range | 41.54 - 43.70 |
52 Week Range | 27.30 - 101.30 |
Volume | |
Avg. Volume | 1,334,691 |
Market Cap | 2.935B |
Beta (5Y Monthly) | 0.91 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -13.55 |
Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 54.24 |
Subscribe to Yahoo Finance Plus to view Fair Value for MRTX
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development biotechnology company, today announced several presentations to be unveiled at the European Society of Medical Oncology Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain, including updated clinical data showcasing the feasibility and potential of the investigational combination of KRASG12C inhibitor, adagrasib with pembrolizumab in a study of treatment naïve patients with advanced non-small ce
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib (KRAZATI®) in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).